Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Share-based Compensation (2016 - 2025)

Northwest Biotherapeutics' Share-based Compensation history spans 16 years, with the latest figure at $185000.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $185000.0 for Q4 2025, down 59.25% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (down 65.08% YoY), and the annual figure for FY2025 was $1.2 million, down 65.08%.
  • Share-based Compensation for Q4 2025 was $185000.0 at Northwest Biotherapeutics, down from $273000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $9.8 million in Q1 2021 to a low of $185000.0 in Q4 2025.
  • The 5-year median for Share-based Compensation is $1.0 million (2023), against an average of $1.8 million.
  • Peak annual rise in Share-based Compensation hit 10045.71% in 2021, while the deepest fall reached 96.75% in 2021.
  • Year by year, Share-based Compensation stood at $866000.0 in 2021, then surged by 195.27% to $2.6 million in 2022, then tumbled by 38.4% to $1.6 million in 2023, then plummeted by 71.17% to $454000.0 in 2024, then plummeted by 59.25% to $185000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $185000.0, $273000.0, and $364000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.